Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels…
(Reuters) -Verve Therapeutics said on Tuesday that it had paused enrollment for an early-stage study testing its experimental gene editing therapy for high cholesterol after a patient experienced a severe drug-related adverse event. Shares…
